1. Home
  2. BKYI vs DRMA Comparison

BKYI vs DRMA Comparison

Compare BKYI & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BIO-key International Inc.

BKYI

BIO-key International Inc.

HOLD

Current Price

$3.46

Market Cap

5.7M

Sector

Technology

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.35

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKYI
DRMA
Founded
1993
2014
Country
United States
United States
Employees
N/A
9
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.1M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BKYI
DRMA
Price
$3.46
$1.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
51.1K
39.8K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,302,984.00
N/A
Revenue This Year
$50.61
N/A
Revenue Next Year
$33.33
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
111.81
N/A
52 Week Low
$0.46
$0.59
52 Week High
$5.54
$7.33

Technical Indicators

Market Signals
Indicator
BKYI
DRMA
Relative Strength Index (RSI) 57.47 56.30
Support Level $0.60 $1.13
Resistance Level $5.54 $1.40
Average True Range (ATR) 0.47 0.07
MACD 0.18 0.01
Stochastic Oscillator 59.06 84.68

Price Performance

Historical Comparison
BKYI
DRMA

About BKYI BIO-key International Inc.

BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: